ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

LIVALO
Hyperlipoproteinemias
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

LIVALO Rx

Generic Name and Formulations:
Pitavastatin 1mg, 2mg, 4mg; tabs.

Company:
Kowa Pharmaceuticals America, Inc.

Therapeutic Use:

Indications for LIVALO:

Adjunct to diet: To reduce elevated total-C, LDL-C, ApoB, and TG, and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia.

Limitations Of use:

Do not exceed 4mg once daily dosing. Effect on cardiovascular morbidity and mortality has not been determined. Not studied in Fredrickson Type I, III, and V dyslipidemias.

Adult:

Individualize. Initially 2mg once daily; may increase after 4 weeks to max 4mg once daily. Moderate to severe renal impairment (CrCl <60mL/min, or ESRD with hemodialysis): 1mg once daily; max 2mg once daily. Concomitant erythromycin: max 1mg daily. Concomitant rifampin: max 2mg daily.

Children:

Not established.

Contraindications:

Active liver disease. Unexplained, persistent elevated serum transaminases. Concomitant cyclosporine. Pregnancy. Nursing mothers.

Warnings/Precautions:

Discontinue if myopathy or markedly elevated CK levels occur; suspend if a predisposition to development of renal failure secondary to rhabdomyolysis develops. Risk factors for myopathy (eg, renal impairment, inadequately treated hypothyroidism, age ≥65yrs). Monitor liver function prior to initiation and repeat as clinically indicated. Interrupt therapy if serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs; do not restart if alternate etiology not found. Substantial alcohol ingestion. Females of reproductive potential should use effective contraception during treatment.

Interactions:

Potentiated by cyclosporine (see Contraindications). Avoid gemfibrozil. Increased risk of myopathy with concomitant fibrates, colchicine, niacin (consider reducing pitavastatin dose); caution. Potentiated by erythromycin, rifampin (see Adult dose). Monitor warfarin.

Pharmacological Class:

HMG-CoA reductase inhibitor.

Adverse Reactions:

Myalgia, back/extremity pain, diarrhea, constipation, elevated creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin; myopathy, rhabdomyolysis with renal dysfunction, hypersensitivity reactions, increases HbA1c and fasting serum glucose levels; rare: cognitive impairment, fatal/non-fatal hepatic failure, immune-mediated necrotizing myopathy.

How Supplied:

Tabs—90

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs